Prof Mark Hatherill, director at SA Tuberculosis Vaccine Initiative at UCT said: “These results tell us that ID93 + GLA-SE should be tested at the end of treatment as a vaccine to prevent recurrent TB. The next logical step is to test whether the vaccine can be given earlier during TB treatment to improve treatment outcomes.”
According to a study done jointly by the Desmond Tutu TB Centre at UCT and the University of Amsterdam, the rate of recurrent TB was 16.4 per 1,000 person-years and increased per subsequent episode 8.4-fold, from 14.6 to 122.7 per 1,000 from episode 2 to episode 6, respectively. Researchers observed similar increases when results were stratified according to HIV status.
Researchers argue that recurrent disease is a major limiting factor in efforts to shorten and simplify the six-month standard treatment course for drug-sensitive TB and the longer and more toxic treatment regimens for drug-resistant TB. A vaccine that lowers rates of disease recurrence might allow shorter and less toxic TB treatment regimens.
Prof Tom Scriba also from SATVI at UCT noted that TB patients typically already have substantial levels of T-cell responses to the TB germ. It was not known if vaccination after the TB was cured would be capable of modulating or boosting these pre-existing T- cell responses.
Source: Education Headlines (educationheadlines.net)
Mainstream media completely failed to report the true facts of the so-called pandemic“Covid19 Crisis” is A Crime Against Humanity | German Corona Investigative Committee - Mandela would be extremely disappointed on how low we have sunk - Putting our Democracy on hold!